687 related articles for article (PubMed ID: 21233014)
21. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study.
Sun Y; Guo W; Bai Y; Ge M; Hu C; Wu S; Hao J; Gao M; Pan J; Dong P; Wu Y; Liang H; Wei Q; Zhong M; Lu T
Oral Dis; 2020 Mar; 26(2):285-294. PubMed ID: 31830347
[TBL] [Abstract][Full Text] [Related]
23. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Katori H; Tsukuda M
Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Psyrri A; Fortpied C; Koutsodontis G; Avgeris M; Kroupis C; Goutas N; Menis J; Herman L; Giurgea L; Remenár É; Degardin M; Pateras IS; Langendijk JA; van Herpen CML; Awada A; Germà-Lluch JR; Kienzer HR; Licitra L; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2213-2218. PubMed ID: 28651338
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
27. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Pignon JP; Syz N; Posner M; Olivares R; Le Lann L; Yver A; Dunant A; Lewin F; Dalley DN; Paccagnella A; Taylor SG; Domenge C; Bourhis J; Mazumdar M
Anticancer Drugs; 2004 Apr; 15(4):331-40. PubMed ID: 15057136
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M
Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365
[TBL] [Abstract][Full Text] [Related]
30. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
31. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Sher DJ; Posner MR; Tishler RB; Sarlis NJ; Haddad RI; Holupka EJ; Devlin PM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e813-8. PubMed ID: 21300455
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
[TBL] [Abstract][Full Text] [Related]
33. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
36. Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.
Schell A; Ley J; Wu N; Trinkaus K; Wildes TM; Michel L; Thorstad W; Gay H; Lewis J; Rich J; Diaz J; Paniello RC; Nussenbaum B; Adkins DR
Cancer Med; 2015 Apr; 4(4):481-9. PubMed ID: 25619559
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Szturz P; Vinches M; Remenár É; van Herpen CML; Abdeddaim C; Stewart JS; Fortpied C; Vermorken JB
Eur J Cancer; 2021 Oct; 156():109-118. PubMed ID: 34425403
[TBL] [Abstract][Full Text] [Related]
38. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
[TBL] [Abstract][Full Text] [Related]
40. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Inhestern J; Schmalenberg H; Dietz A; Rotter N; Maschmeyer G; Jungehülsing M; Grosse-Thie C; Kuhnt T; Görner M; Sudhoff H; Wittekindt C; Guntinas-Lichius O
Ann Oncol; 2017 Aug; 28(8):1917-1922. PubMed ID: 28498880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
